Healthcare
LIXTE Biotechnology Advances LB-100 as a Novel Cancer Treatment Enhancer
LIXTE Biotechnology's LB-100, a first-in-class PP2A inhibitor, aims to boost the effectiveness of existing chemotherapies and immunotherapies in hard-to-treat cancers, with ongoing clinical trials for ovarian, colon, and soft tissue sarcomas.
Soligenix Reports Encouraging Interim Data and Positive Comparative Results for CTCL Therapy
Soligenix released promising interim analysis from its phase 3 FLASH2 study and positive comparative results for HyBryte versus Valchlor, reinforcing its progress in developing treatments for cutaneous T-cell lymphoma.
Gallup Survey Reveals Growing Use of AI to Supplement Healthcare Visits
A Gallup and West Health survey found that many Americans are using AI tools to complement their healthcare interactions, with usage patterns varying by age, income, and motivation, highlighting implications for providers and policymakers.
Study Reveals AI Medical Diagnosis Errors Exceed 80%, Raising Safety Concerns
A new study finds that generative AI systems make diagnostic errors in over 80% of cases, highlighting significant limitations in reasoning for clinical use.
Half a Million Post-9/11 U.S. Veterans Have High Blood Pressure, Many Undiagnosed
A new study reveals that about half a million younger post-9/11 veterans have high blood pressure, with many undiagnosed or untreated, highlighting critical gaps in cardiovascular care.
HeartBeam Closes $10M Public Offering to Fund Commercialization of ECG Technology
HeartBeam raised $10 million in a public offering to advance its FDA-cleared 12-lead synthesized ECG system and heart attack detection technologies, positioning the company for expanded market reach.
Precision Oncology Shifts to Combination Strategies as Resistance Challenges Persist
Cancer treatment is increasingly moving toward multi-drug regimens that combine targeted therapies with immunotherapy and chemotherapy, with Lixte Biotechnology's first-in-class PP2A inhibitor LB-100 designed to enhance existing treatments by disrupting cancer cell repair and boosting immune activity.
Biotech Valuation Shift: Drug Pipeline Progress Now Measured as Financial Assets Under GAAP
The biotech sector is experiencing a transformation where advancing drug pipelines are increasingly valued as financial assets under fair-value accounting, with companies like Oncotelic Therapeutics exemplifying how clinical progress directly impacts balance sheet valuation.
Ocumetics Reports Life-Changing Six-Month Results from First-in-Human Study of Accommodating Intraocular Lens
Ocumetics Technology Corp. announced that six-month postoperative results from its first-in-human study of the Ocumetics Accommodating Intraocular Lens show continued vision improvements and meaningful quality-of-life enhancements for patients, with plans to advance to Group Two surgeries.
Helus Pharma CEO Steps Down, Co-founder Eric So Appointed Interim Chief
Helus Pharma announced the immediate resignation of CEO Michael Cola and appointment of co-founder Eric So as interim CEO, aiming to ensure continuity during a pivotal phase with upcoming Phase 3 trial results.
Lantern Pharma Seeks FDA Feedback on HARMONIC Trial Protocol Amendments for Lung Cancer Drug
Lantern Pharma has scheduled a Type C meeting with the FDA to discuss proposed changes to its Phase 2 HARMONIC trial for LP-300 in non-small cell lung cancer, focusing on EGFR Exon 21 L858R patients based on promising clinical data.
Aditxt Subsidiary's Protein Analysis Platform Shows Promise in Breast Cancer Treatment Study
A study published in npj Precision Oncology found that Ignite Proteomics' protein analysis platform provided more predictive insight into metastatic breast cancer treatment outcomes than traditional methods, potentially improving treatment selection.
Oragenics Reports Early Progress in Phase IIa Trial of Intranasal Concussion Therapy
Oragenics Inc. has enrolled two patients and administered eight doses in its Phase IIa trial for ONP-002, a potential first-in-class intranasal treatment for mild traumatic brain injury, addressing a significant unmet medical need in a market with no FDA-approved pharmacological therapies.
Soligenix CEO Advocates for Patient-Centric Reformulation Strategy in Rare Disease Drug Development
Soligenix CEO Christopher Schaber argues that reformulating therapies to better fit patients' daily lives can improve access, adherence, and long-term viability, highlighting a strategic shift in biopharmaceutical development.
MindBio Therapeutics Expands AI Intoxication Detection with New Data Collection Platform
MindBio Therapeutics has launched Intox Collect™, broadening its AI-driven intoxication detection capabilities beyond alcohol to include multiple central nervous system stimulants and depressants, with implications for workplace safety across high-risk industries.
Soligenix Gains European Orphan Drug Designation for Behçet's Disease Therapy SGX945
The European Commission granted orphan drug designation to Soligenix's SGX945 for treating Behçet's disease, validating the therapy's potential and providing regulatory and commercial incentives for development in a rare disease area with significant unmet need.
Cardio Diagnostics Holdings Leverages AI and Epigenetics for Advanced Cardiovascular Disease Management
Cardio Diagnostics Holdings is advancing cardiovascular disease prevention and detection through an AI-driven platform that integrates genetics and epigenetics to provide personalized insights.
LIXTE Biotechnology's LB-100 Represents Novel Cancer Treatment Approach Through PP2A Inhibition
LIXTE Biotechnology Holdings is advancing LB-100, a first-in-class PP2A inhibitor designed to enhance existing cancer therapies by making tumors more responsive to chemotherapy and immunotherapy in multiple clinical programs targeting solid tumors with significant unmet medical need.
Formycon to Announce 2025 Financial Results and Participate in Key Investor Conferences
Formycon AG will release its 2025 financial results and provide a 2026 outlook during an April conference call, while planning participation in multiple international investor conferences to showcase its biosimilar pipeline amid growing market opportunities.
BioXgen Seeks Crowdfunding Investment for Cardiac Patch Targeting Post-Surgery Complication
BioXgen is launching a Regulation Crowdfunding investment round and hosting a webinar to demonstrate its cardiac patch designed to prevent postoperative atrial fibrillation, a common complication affecting nearly half of open-heart surgery patients.
New Oral Rinse Demonstrates Superior Gingivitis Protection in Saliva Environment
ioRinse Ultra has shown complete elimination of gingivitis-causing bacteria within 30 seconds in saliva-inclusive testing, addressing a critical gap in traditional oral rinse evaluation that could transform daily oral care routines.
Molecular Testing Gains Importance in Complex CNS Cancer Diagnosis and Treatment
Molecular analysis is becoming crucial for identifying and treating complex central nervous system tumors, which traditional methods often miss, with companies like CNS Pharmaceuticals advancing targeted drug development.
NanoViricides Highlights NV-387 as Potential Measles Treatment Amid Global Outbreak Concerns
NanoViricides announced its antiviral drug candidate NV-387 may address the growing global measles outbreak, potentially complementing vaccination efforts by reducing transmission and treating infected patients.
Oncotelic Therapeutics Featured in Editorial on Biotech Valuation Trends
Oncotelic Therapeutics' diversified pipeline and strategic holdings, including a 45% stake in GMP Bio valued at over $1 billion, exemplify how scientific progress and commercialization proximity are increasingly recognized as measurable financial assets under U.S. GAAP, reflecting a broader shift in biotech valuation.
Soligenix CEO Emphasizes Capital Discipline as Key to Biotech Success in Constrained Funding Environment
Soligenix CEO Dr. Christopher J. Schaber highlights capital discipline as essential for biotech companies to navigate today's challenging funding landscape, where strategic resource allocation and milestone-focused development are critical for attracting investment and advancing programs toward commercialization.
Soligenix CEO Advocates for Patient-Centric Drug Reformulation to Improve Treatment Access and Adherence
Soligenix CEO Christopher Schaber argues that reformulating therapies to better align with patients' daily lives can enhance treatment access, adherence, and clinical trial success, reflecting a broader industry shift toward patient-centered drug development.
South Ogden Orthodontic Practice Emphasizes Personalized Care and Advanced Technology
Albrechtsen & Fanelli Orthodontics in South Ogden provides comprehensive orthodontic services using advanced technology and personalized treatment approaches for both children and adults.
Babston Oral Surgery Expands Dental Implant Services in Mobile, Enhancing Patient Access to Permanent Tooth Replacement Solutions
Babston Oral Surgery's expansion of dental implant services in Mobile addresses critical oral health needs by providing permanent tooth replacement options that improve both function and quality of life for patients.
New Book Addresses Mental Health Crisis Through Faith-Based Approach
Dr. Walter Malone Jr.'s new book 'Tailored to Win' offers biblical solutions to rising anxiety and depression rates, providing practical guidance for finding purpose and spiritual strength.
BRYGE AI Wins Silver Stevie Award for Women-Focused Health Technology Innovation
BRYGE AI's recognition at the 2025 Stevie Awards for Women in Business highlights the growing importance of technology solutions addressing communication challenges faced by women with ADHD in professional and personal settings.